A breakthrough in lung cancer treatment may be on the horizon. Scientists at VCU Massey Comprehensive Cancer Center have ...

Understanding your tumor biology is key to finding the right treatment for pancreatic cancer. Identifying mutations, or changes in a [...] READ MORE ...

Researchers have identified a range of genetic alterations that may lead to resistance to KRAS G12C inhibitors in patients ...

For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. | For a while, special ...

Clinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public ...

The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...

Verastem's assets, Avutometinib and Defactinib, show promising results in treating KRAS-mutated LGSOC. Read why VSTM stock is a Hold.

Colorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic ...

ALTA3263 is a potential best-in-class KRAS-selective small molecule inhibitor that potently targets >90% of KRAS mutations ALTA3263 is designed for complete KRAS target coverage, which will be ...

Initial validation using orthotopic models: SIL204 administered subcutaneously (systemically) showed significant efficacy in ...

In a move straight out of 2021, BridgeBio Oncology is taking the SPAC route to the public markets in a deal with Helix ...

ALTA3263 is an oral KRAS-selective inhibitor specifically designed to potently inhibit the KRAS “ON” (active) state of greater than 90% of all KRAS mutations and to provide complete target ...